<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836507</url>
  </required_header>
  <id_info>
    <org_study_id>CRC01-01</org_study_id>
    <nct_id>NCT04836507</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients</brief_title>
  <official_title>An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curocell Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Curocell Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in&#xD;
      adult patients with relapsed or refractory large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Pivotal Study: Overall Response Rate (ORR)</measure>
    <time_frame>5 years</time_frame>
    <description>ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immunogenicity to CRC01</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignancy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax) of CRC01 transduced cells into target tissues</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUC) of CRC01 transduced cells into target tissues</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (Tmax) of CRC01 transduced cells into target tissues</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">91</enrollment>
  <condition>Relapsed Large B-cell Lymphoma</condition>
  <condition>Refractory Large B-cell Lymphoma</condition>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Primary Mediastinal Large B-Cell Lymphoma (PMBCL)</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <condition>Transformed Follicular Lymphoma (TFL)</condition>
  <arm_group>
    <arm_group_label>CRC01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRC01</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.</description>
    <arm_group_label>CRC01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>CRC01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>CRC01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 19 years of age and provided written informed consent&#xD;
&#xD;
          2. Histologically confirmed following large B-cell lymphomas according to the World&#xD;
             Health Organization classification 2017&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma, not otherwise specified Including Large cell&#xD;
                  transformation from follicular lymphoma (Transformed follicular lymphoma)&#xD;
&#xD;
               -  High-grade B-cell lymphoma, not otherwise specified&#xD;
&#xD;
               -  High-grade B-cell lymphoma with double-hit/triple-hit&#xD;
&#xD;
               -  Primary mediastinal large B cell lymphoma&#xD;
&#xD;
          3. Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab,&#xD;
             anthracycline and either having failed autologous Hematopoietic stem cell&#xD;
             transplantation (ASCT) or being ineligible for or not consenting to ASCT.&#xD;
&#xD;
          4. At least one measurable lesion (Long diameter ≥ 1.5cm)&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          6. Adequate renal and hepatic functions based on the laboratory test results&#xD;
&#xD;
               -  Total Bilirubin ≤ 2.0mg/dL with the exception of patients with&#xD;
                  Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be&#xD;
                  included if their total bilirubin is ≤ 3 X ULN and direct bilirubin ≤ 1.5 X ULN.&#xD;
&#xD;
               -  Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 X Upper Limit of&#xD;
                  Normal (ULN) for age with exception of liver metastasis; patients with liver&#xD;
                  metastasis may be included if their AST and ALT are ≤ 5 X ULN.&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 X ULN&#xD;
&#xD;
               -  Estimated Glomerular Filtration Rate (eGFR) ≥ 60mL/min/1.73m2&#xD;
&#xD;
          7. Adequate hematologic function without transfusions within 2 weeks prior to screening&#xD;
             for the study defined as followings:&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0g/㎗&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) &gt; 1,000/㎕&#xD;
&#xD;
               -  Absolute Lymphocyte Count (ALC) ≥ 300/㎕&#xD;
&#xD;
               -  Platelets ≥ 50,000/㎕&#xD;
&#xD;
          8. Must have a minimum level of pulmonary reserve defined as;&#xD;
&#xD;
               -  ≤ Grade 1 dyspnea per Common terminology criteria for adverse events (CTCAE) v5.0&#xD;
&#xD;
               -  pulse oxygenation &gt; 91% on room air&#xD;
&#xD;
          9. Hemodynamically stable, without pericardial effusion and Left Ventricle Ejection&#xD;
             Fraction (LVEF) ≥ 50% confirmed by Echocardiogram (ECG) or Multigated Radionuclide&#xD;
             Angiography (MUGA)&#xD;
&#xD;
         10. Must have an apheresis product of non-mobilized cells accepted for manufacturing&#xD;
&#xD;
         11. Life expectancy ≥ 12 weeks&#xD;
&#xD;
         12. Women of child-bearing potential and all male participants must agree to use highly&#xD;
             effective methods of contraception for at least 12 months following CRC01 infusion and&#xD;
             until CRC01 are no longer present by PCR on two consecutive tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following medical history&#xD;
&#xD;
               -  Previous or concurrent malignancy with the following exceptions:&#xD;
&#xD;
                    -  Adequately treated basal cell or squamous cell carcinoma without evidence of&#xD;
                       recurrence for at least 3 years prior to the study&#xD;
&#xD;
                    -  In situ carcinoma of the cervix or breast, treated curatively and without&#xD;
                       evidence of recurrence for at least 3 years prior to the study&#xD;
&#xD;
                    -  A primary malignancy which has been completely resected and in complete&#xD;
                       remission for ≥ 5 years&#xD;
&#xD;
               -  Unstable angina and/or myocardial infarction within 12 months prior to screening&#xD;
&#xD;
               -  Thromboembolic events, pulmonary embolism or bleeding diatheses within 6 months&#xD;
                  prior to screening&#xD;
&#xD;
               -  Hypoxemia, significant pleural effusion or significant EKG findings within 6&#xD;
                  months prior to the screening&#xD;
&#xD;
          2. Patients with the following concurrent disease at screening:&#xD;
&#xD;
               -  Central Nervous System (CNS) involvement by malignancy by MRI at screening&#xD;
&#xD;
               -  Active infection with hepatitis B (HBsAg positive. But, in case of HBcAb IgG&#xD;
                  positive, the patient can be enrolled in this study if he/she takes prophylactic&#xD;
                  anti-viral agent.)&#xD;
&#xD;
               -  Active infection with hepatitis C (HCV RNA positive)&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
               -  Active neurological auto-immune or inflammatory disorder (e.g. Guillain Barre&#xD;
                  Syndrome, Amyotrophic Lateral Sclerosis)&#xD;
&#xD;
               -  Ventricular tachycardia and atrial fibrillation with rapid ventricular response&#xD;
                  not controlled with medical treatment within 3 months prior to screening&#xD;
&#xD;
          3. Rapidly progressing the disease as per investigator's discretion&#xD;
&#xD;
          4. Had major surgery requiring general anesthesia or mechanical ventilation within 4&#xD;
             weeks prior to screening (For video-assisted thoracoscopic surgery (VATS) or&#xD;
             open-and-closed (ONC) surgery can be applied with within 2 weeks prior to screening.)&#xD;
&#xD;
          5. Severe infection requiring anti-bacterial, anti-fungal or anti-viral medication or&#xD;
             uncontrolled active infection&#xD;
&#xD;
          6. The following treatment history is excluded:&#xD;
&#xD;
               -  Prior treatment with any prior anti-CD19/anti-CD3 therapy or any other anti-CD19&#xD;
                  therapy&#xD;
&#xD;
               -  Prior treatment with any adoptive T cell therapy&#xD;
&#xD;
               -  Treatment with any prior gene therapy product&#xD;
&#xD;
               -  Prior allogeneic HSCT&#xD;
&#xD;
               -  Patients on oral anticoagulation therapy&#xD;
&#xD;
          7. Eligible for and consenting to ASCT&#xD;
&#xD;
          8. Use of investigational medicinal product/device within 4 weeks prior to screening&#xD;
&#xD;
          9. Pregnant or lactating women&#xD;
&#xD;
         10. Hypersensitivity reaction to the excipients of CRC01 cell product&#xD;
&#xD;
         11. The following treatments are excluded:&#xD;
&#xD;
               -  Anti-neoplastic therapies including chemotherapy, biologic agents, retinoid&#xD;
                  therapy, radiotherapy, immune therapy, hormonal therapy, etc. other than&#xD;
                  lymphodepleting chemotherapy within 2 weeks of leukapheresis and within 2 weeks&#xD;
                  of CRC01 infusion&#xD;
&#xD;
               -  Steroids: therapeutic doses of steroids must be stopped &gt; 7 days prior to&#xD;
                  leukapheresis and &gt; 5 days prior to CRC01 infusion. However, the following&#xD;
                  physiological replacement doses of steroids are allowed: &lt; 6 mg/m2/day&#xD;
                  hydrocortisone or equivalent&#xD;
&#xD;
               -  Immunosuppression: any immunosuppressive medication must be stopped &gt; 4 weeks&#xD;
                  prior to leukapheresis and &gt; 4 weeks prior to CRC01 infusion&#xD;
&#xD;
               -  Antibody use including anti-CD20 therapy within 4 weeks prior to CRC01 infusion&#xD;
&#xD;
               -  CNS disease prophylaxis must be stopped &gt; 1 week prior to CRC01 infusion (e.g.&#xD;
                  intrathecal methotrexate)&#xD;
&#xD;
        Other protocol-related inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bom-I Kwon, BSc</last_name>
    <phone>+82428633698</phone>
    <email>bikwon@curocellbtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunsoo Kim, MSc</last_name>
    <email>gskim@curocellbtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonseog Kim, MD, PhD</last_name>
      <phone>+821099335823</phone>
      <email>wonseog.kim@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC01</keyword>
  <keyword>anti-CD19 CAR-T</keyword>
  <keyword>CAR-T</keyword>
  <keyword>CAR T cells</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>PD-1 knock down</keyword>
  <keyword>TIGIT knock down</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

